Loki Therapeutics

Funding and NIH signals

• NIH award NIH awarded $727K (STTR Phase II 4R42CA287679-02, extension, notice Sep 17, 2026). NIH RePORTER 4R42CA287679-02 (Sep 17, 2026)
  Evidence (1 event)

  • Sep 17, 2026 · NIH RePORTER 4R42CA287679-02
    Organization: LOKI THERAPEUTICS, INC; City/State: Sa, CA; Project number: 4R42CA287679-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 726592; Administering IC: National Cancer Institute; Project title: Clinical testing of Listeria-TT and Gemcitabine in a Phase I clinical trial with PDAC patients; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals